Akter Mafruha, Khan Mohiuddin Ahmed, Dey Bimalangshu R
BMT Unit, Department of Hematology, Dhaka Medical College Hospital (DMCH).
Massachusetts General Hospital (MGH), Harvard Medical School, Boston, USA.
Blood Cell Ther. 2020 Feb 25;3(1):1-5. doi: 10.31547/bct-2019-006.
We are describing eleven autologous hematopoietic stem cell transplants (ASCT) that were performed in 2016 at three different transplant centers in Bangladesh. Indications for those patients were multiple myeloma (MM) (n=4), diffuse large B cell lymphoma (DLBCL) (n=2), Hodgkin's lymphoma (HD) (n=2), peripheral T cell lymphoma (PTCL) (n=1), acute myeloid leukemia (AML) (n=1), and acute promyelocytic leukemia (APL) (n=1). All autologous stem cell products were cryo-preserved and transfused back to patients freshly thawed at 37℃. All were in second remission (CR2) except for the PTCL patient, who was in first remission (CR1). The bone marrow transplant (BMT) program was first initiated in Bangladesh in March 2014 at the Dhaka Medical College Hospital (DMCH), the country's largest and the leading government-run public hospital, in collaboration with the Massachusetts General Hospital in Boston, USA. Subsequently, two more centers, Apollo Hospitals Dhaka and the Combined Military Hospital (CMH), started transplant programs in 2016. Seven out of eleven ASCT were performed at the DMCH center, with two at Apollo Hospitals and two at CMH Dhaka. The median age for all patients was 39 (range 18-67) and the Male: Female ratio was 9: 2. The average time to neutrophil and platelet engraftment was day 9 (range 8-12) and day 12 (range 9-15), respectively. Major early complications were neutropenic fever, mucositis, and infection. There was no transplant related mortality (TRM) within the first 100 days. Over a median follow up of 2 years, overall survival is 82.0% and progression free survival is 63.6%.
我们正在描述2016年在孟加拉国三个不同移植中心进行的11例自体造血干细胞移植（ASCT）。这些患者的适应症包括多发性骨髓瘤（MM）（n = 4）、弥漫性大B细胞淋巴瘤（DLBCL）（n = 2）、霍奇金淋巴瘤（HD）（n = 2）、外周T细胞淋巴瘤（PTCL）（n = 1）、急性髓系白血病（AML）（n = 1）和急性早幼粒细胞白血病（APL）（n = 1）。所有自体干细胞产品均进行了冷冻保存，并在37℃新鲜解冻后回输给患者。除处于首次缓解期（CR1）的PTCL患者外，所有患者均处于第二次缓解期（CR2）。骨髓移植（BMT）项目于2014年3月在孟加拉国最大的政府运营公立医院达卡医学院医院（DMCH）与美国波士顿的麻省总医院合作首次启动。随后，另外两个中心，达卡阿波罗医院和联合军事医院（CMH），于2016年开始了移植项目。11例ASCT中有7例在DMCH中心进行，2例在阿波罗医院，2例在达卡CMH。所有患者的中位年龄为39岁（范围18 - 67岁），男女比例为9:2。中性粒细胞和血小板植入的平均时间分别为第9天（范围8 - 12天）和第12天（范围9 - 15天）。主要的早期并发症为中性粒细胞减少性发热、粘膜炎和感染。前100天内无移植相关死亡率（TRM）。中位随访2年，总生存率为82.0%，无进展生存率为63.6%。
